Powered by

The Health 202: Years after an experimental stem cell therapy blinded patients, the FDA is still trying to stop it

Apr 04, 2019 - Washington Post Blogs
Board and Executive Moves


The Food and Drug Administration promised yesterday to heighten oversight of providers of experimental stem cell treatments, as a Post report detailed the agency's slow response to a leading stem cell company whose treatments blinded some patients.

U.S. Stem Cell had $6.7 million in revenue last year, operates three clinics and has trained doctors at 150 others, making it a leading stem cell treatment provider in the burgeon...